Probiotic in the Treatment of CRE carriage
Research type
Research Study
Full title
Randomised Open Label Control Feasibility Study of Probiotic in the treatment of faecal carriage Carbapenemase- bearing Klebsiella pneumoniae. PITFALL
IRAS ID
257051
Contact name
Timothy Felton
Contact email
Sponsor organisation
Manchester University NHS Foundation Trust
ISRCTN Number
ISRCTN11133689
Duration of Study in the UK
1 years, 0 months, 1 days
Research summary
Antibiotic resistance of Gram-negative bacteria, particularly the Enterobacteriaceae is a major global concern. Manchester is known to have a higher spread of carbapenem resistant Klebsiella Pneumoniae which combines virulence, high transmissibility and transmissible resistance to almost all antibiotics.Traditional approaches, such as antimicrobial stewardship and infection control, are unlikely to reverse the spread of carbapenem-resistant Enterobacteriaceae. The probiotic species Lactobacillus reuteri inhibits Enterobacteriaceae and its administration reduces their counts in the infant gut; it is now used in paediatric practice to treat carriage of resistant strains of Enterobacteriaceae, including Klebsiella pneumoniae. We propose a randomised, open label controlled feasibility study in Manchester in immuno-competent adults known to be colonised with multi-resistant K pneumoniae. We will investigate whether any falls in faecal counts of multi-resistant K pneumoniae seen after the administration of a probiotic are greater than any falls seen in the control group. We will also investigate whether a lower proportion of the final faecal samples from probiotic-receiving than from control subjects yields multi-resistant K pneumoniae on culture.
REC name
North West - Greater Manchester Central Research Ethics Committee
REC reference
18/NW/0863
Date of REC Opinion
26 Mar 2019
REC opinion
Further Information Favourable Opinion